John P Prybylski

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 12

Top Topics

Decision Making

Clinical Evaluation

Atopic Dermatitis

Coronary Artery Disease

Top Venues

Journal of pharmacokinetics and pharmacodynamics

Clinical pharmacokinetics

The AAPS journal

CPT: pharmacometrics & systems pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield, Timothy Nicholas
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of pharmacokinetics and pharmacodynamics (2024)
John P Prybylski
Indirect modeling of derived outcomes: Are minor prediction discrepancies a cause for concern? CPT: pharmacometrics & systems pharmacology (2024)
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield, Timothy Nicholas
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield, Timothy Nicholas
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
John P Prybylski, Yuchen Wang, Vaishali Sahasrabudhe, Vivek Purohit
Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach. The AAPS journal 26 (4) (2024)
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield, Timothy Nicholas
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield, Timothy Nicholas
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
John P Prybylski
Reporting Coefficient of Variation for Logit, Box-Cox and Other Non-log-normal Parameters. Clinical pharmacokinetics (2024)
John P Prybylski
Reporting Coefficient of Variation for Logit, Box-Cox and Other Non-log-normal Parameters. Clinical pharmacokinetics 63 (2) (2024)
John P Prybylski, Yuchen Wang, Vaishali Sahasrabudhe, Vivek Purohit
Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach. The AAPS journal 26 (4) (2024)
John P Prybylski
Reporting Coefficient of Variation for Logit, Box-Cox and Other Non-log-normal Parameters. Clinical pharmacokinetics 63 (2) (2024)
John P Prybylski
Reporting Coefficient of Variation for Logit, Box-Cox and Other Non-log-normal Parameters. Clinical pharmacokinetics 63 (2) (2024)